Literature DB >> 12132046

GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation.

S K Sohn1, J G Kim, K W Seo, Y S Chae, J T Jung, J S Suh, K B Lee.   

Abstract

It is important to optimize methods to mobilize hematopoietic stem cells into peripheral blood (PB) for successful allogeneic peripheral blood stem cell (PBSC) transplantation. Our primary intent was to investigate the role of GM-CSF for mobilization in normal healthy donors and to compare its efficacy in mobilizing stem cells alone, in concurrent combination and in sequential combination with G-CSF in this study. We analyzed the results of the PBSC harvest through large volume leukapheresis from 48 normal healthy donors mobilized by three different regimens including GM-CSF. Donors were assigned sequentially to one of the following regimens for mobilization: GM-CSF 10 microg/kg/day alone (group 1, n = 9); concurrent combination (group 2, n = 20) of G-CSF 5 microg/kg/day and GM-CSF 5 microg/kg/day; sequential combination (group 3, n = 19) of GM-CSF alone 10 microg/kg/day for 3 days followed by G-CSF alone 10 microg/kg/day for 2-3 days. The harvested CD34(+) cell count (P < 0.05) was statistically higher in group 3 than in group 1 or 2. Pre-collection WBC count in donors (P < 0.05), harvested MNC (P < 0.05) and CD3(+) cell count (P < 0.05) of group 2 or 3 were significantly higher than those of group 1. Recipients who received stem cells mobilized with combination regimens showed an earlier recovery of WBC and platelets count than those with GM-CSF alone. The incidence of acute graft-versus-host disease was not statistically different among three recipient groups. GM-CSF-based mobilization was well tolerated in normal healthy donors. The sequential combination regimen appears to be an excellent mobilization strategy and might be preferred as the optimal method in some clinical situations that need a higher number of stem cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12132046     DOI: 10.1038/sj.bmt.1703598

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  6 in total

Review 1.  Diverse clinical applications using advantages of allogeneic peripheral blood stem cell transplantation.

Authors:  Sang Kyun Sohn; Jong Gwang Kim; Dong Hwan Kim; Jin Ho Baek; Kyu Bo Lee
Journal:  Int J Hematol       Date:  2004-06       Impact factor: 2.490

2.  In Vivo Mobilization and Functional Characterization of Nonhuman Primate Monocytic Myeloid-Derived Suppressor Cells.

Authors:  A F Zahorchak; M B Ezzelarab; L Lu; H R Turnquist; A W Thomson
Journal:  Am J Transplant       Date:  2015-09-15       Impact factor: 8.086

Review 3.  GM-CSF: A Double-Edged Sword in Cancer Immunotherapy.

Authors:  Anil Kumar; Adeleh Taghi Khani; Ashly Sanchez Ortiz; Srividya Swaminathan
Journal:  Front Immunol       Date:  2022-07-05       Impact factor: 8.786

4.  Clinical significance of platelet count at day +60 after allogeneic peripheral blood stem cell transplantation.

Authors:  Dong Hwan Kim; Sang Kyun Sohn; Jin Ho Baek; Jong Gwang Kim; Nan Young Lee; Dong Il Won; Jang Soo Suh; Kyu Bo Lee
Journal:  J Korean Med Sci       Date:  2006-02       Impact factor: 2.153

Review 5.  An Overview on Promising Somatic Cell Sources Utilized for the Efficient Generation of Induced Pluripotent Stem Cells.

Authors:  Arnab Ray; Jahnavy Madhukar Joshi; Pradeep Kumar Sundaravadivelu; Khyati Raina; Nibedita Lenka; Vishwas Kaveeshwar; Rajkumar P Thummer
Journal:  Stem Cell Rev Rep       Date:  2021-06-07       Impact factor: 5.739

6.  Human finger-prick induced pluripotent stem cells facilitate the development of stem cell banking.

Authors:  Hong-Kee Tan; Cheng-Xu Delon Toh; Dongrui Ma; Binxia Yang; Tong Ming Liu; Jun Lu; Chee-Wai Wong; Tze-Kai Tan; Hu Li; Christopher Syn; Eng-Lee Tan; Bing Lim; Yoon-Pin Lim; Stuart A Cook; Yuin-Han Loh
Journal:  Stem Cells Transl Med       Date:  2014-03-19       Impact factor: 6.940

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.